Latest & greatest articles for budesonide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on budesonide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on budesonide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for budesonide

61. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients (PubMed)

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients The adjustable-dose budesonide/formoterol dry powder inhaler (DPI) has demonstrated similar or greater asthma control with less inhaled corticosteroid compared with the fixed-dose budesonide/formoterol DPI.We sought to evaluate the efficacy, tolerability, and resource use of maintenance therapy with the adjustable (...) -dose budesonide/formoterol pressurized metered-dose inhaler versus the fixed-dose budesonide/formoterol pressurized metered-dose inhaler and the fixed-dose fluticasone propionate/salmeterol DPI.This was a randomized, open-label, multicenter study of patients (N = 1225) 12 years and older with moderate-to-severe persistent asthma. After 10 to 14 days of current therapy, patients were randomized 2:1 to fixed-dose budesonide/formoterol (160/4.5 microg x 2 inhalations [320/9 microg] twice daily

2008 EvidenceUpdates

62. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. (PubMed)

Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Combination therapies are frequently recommended as maintenance therapy for people with asthma, whose disease is not adequately controlled with inhaled steroids. Fluticasone/salmeterol (FP/SAL) and budesonide/formoterol (BUD/F) have been assessed against their respective monocomponents, but there is a need to compare these two therapies on a head-to-head (...) basis.To estimate the relative effects of fluticasone/salmeterol and budesonide/formoterol in terms of asthma control, safety and lung function.We searched the Cochrane Airways Group register of trials with prespecified terms. We performed additional hand searching of manufacturers' web sites and online trial registries. Searches are current to May 2008.Randomised studies comparing fixed dose FP/SAL and BUD/F were eligible, for a minimum of 12 weeks. Crossover studies were excluded. Our primary

Full Text available with Trip Pro

2008 Cochrane

63. Budesonide for induction of remission in Crohn's disease. (PubMed)

Budesonide for induction of remission in Crohn's disease. Corticosteroids play a key role in the induction of remission in Crohn's disease. However, corticosteroids can cause significant adverse events. Budesonide is an alternate enteral glucocorticoid with limited systemic bioavailability.The primary objective was to evaluate the efficacy and safety of oral budesonide for the induction of remission in Crohn's disease.The following electronic databases were searched: MEDLINE, EMBASE (...) , the Cochrane Central Register of Controlled Trials, the Cochrane IBD/FBD Group Specialised Trial Register, and ClinicalTrials.gov. Reference lists of articles, as well as conference proceedings were manually searched. Pharmaceutical companies were also contacted.Randomized controlled trials comparing budesonide to a control treatment were included. The study population included patients of any age with active Crohn's disease (CDAI > 150). The primary outcome was induction of remission (CDAI < 150) by week

Full Text available with Trip Pro

2008 Cochrane

64. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study (PubMed)

Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study Budesonide is an inhaled steroid with a strong topical effect but with minimal systemic effects; it has been effectively delivered to animal lungs using surfactant as a vehicle. The purposes of this study were to determine whether early intratracheal instillation of budesonide using surfactant as a vehicle would improve pulmonary status, reduce mortality (...) , and reduce chronic lung disease morbidity.We conducted a prospective, randomized blind trial in 116 very low birth weight infants (< 1500 g) who had severe radiographic respiratory distress syndrome and required mechanical ventilation with fraction of inspired oxygen > or = 0.6 shortly after birth: 60 were in the treated group (intratracheal instillation of a mixture of 0.25 mg/kg of budesonide and 100.00 mg/kg of survanta, every 8 hours) and 56 were in the control group (100 mg/kg of survanta only

2008 EvidenceUpdates

65. Budesonide-formoterol for maintenance and as needed reliever treatment reduced asthma exacerbations

Budesonide-formoterol for maintenance and as needed reliever treatment reduced asthma exacerbations Budesonide-formoterol for maintenance and as needed reliever treatment reduced asthma exacerbations | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Budesonide-formoterol for maintenance and as needed reliever treatment reduced asthma exacerbations Article Text Therapeutics Budesonide-formoterol for maintenance and as needed reliever

2008 Evidence-Based Medicine (Requires free registration)

66. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. (PubMed)

Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Beclomethasone dipropionate (BDP) and budesonide (BUD) are commonly prescribed inhaled corticosteroids for the treatment of asthma. Fluticasone propionate (FP) is newer agent with greater potency in in-vitro assays.To compare the efficacy and safety of Fluticasone to Beclomethasone or Budesonide in the treatment of chronic asthma.We searched the Cochrane Airways Group trial register (January 2007 (...) ) and reference lists of articles. We contacted trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997 to 2006).Randomised trials in children and adults comparing Fluticasone to either Beclomethasone or Budesonide in the treatment of chronic asthma.Two reviewers independently assessed articles for inclusion and methodological quality. One reviewer extracted data. Quantitative analyses were undertaken using RevMan analyses 1.0.1.Seventy

2007 Cochrane

67. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy

Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

68. Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma

Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma Article Text Therapeutics Maintenance plus

Full Text available with Trip Pro

2006 Evidence-Based Medicine (Requires free registration)

69. Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations

Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations Article Text Treatment Maintenance and symptom relief with budesonide plus formoterol reduced severe

Full Text available with Trip Pro

2006 Evidence-Based Nursing

70. Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol

Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol Drug Approval Package: Symbicort (budesonide/formoterol fumarate dihydrate) NDA #021929 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol Company: AstraZeneca Pharmaceuticals NDA: 021929 Approval Date: 7/21/2006 (PDF) (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF) (PDF

2006 FDA - Drug Approval Package

71. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. (PubMed)

Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. The contributions of as-needed inhaled corticosteroids and long-acting beta2 agonists (LABA) to asthma control have not been fully established. We compared the efficacy and safety of three reliever strategies: a traditional short-acting beta2 agonist; a rapid-onset LABA (formoterol); and a combination of LABA and an inhaled corticosteroid (budesonide (...) -formoterol) in symptomatic patients receiving budesonide-formoterol maintenance therapy.We did a 12-month, double-blind, parallel-group study in 3394 patients (aged 12 years or older), in 289 centres in 20 countries, who were using inhaled corticosteroids at study entry and symptomatic on budesonide-formoterol (160 microg and 4.5 microg, respectively), one inhalation twice daily, during a 2-week run-in. After run-in, patients were randomly assigned budesonide-formoterol maintenance therapy plus one

2006 Lancet

72. Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief

Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn (...) more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Combined budesonide and formoterol for maintenance and relief provided better asthma

2006 Evidence-Based Medicine (Requires free registration)

73. Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

74. Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study

Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

75. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study

Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

76. Budesonide for induction of remission in Crohn's disease. (PubMed)

Budesonide for induction of remission in Crohn's disease. Corticosteroids continue to play a central role in induction of remission in active Crohn's disease. However, their use comes at a price of significant adverse effects when used repeatedly or for extended periods. Newer corticosteroid agents with limited systemic bioavailability offer a tantalizing option, if they can be shown to be efficacious and safer than conventional corticosteroids. Budesonide is the main alternative corticosteroid (...) currently available in an enteric formulation.To evaluate the effectiveness of oral budesonide for the treatment of acute flares of Crohn's disease. A secondary but important endpoint was to evaluate the adverse effect profile.The following sources were used to search the literature for potentially relevant papers and trials. 1. A computer-assisted search of the on-line bibliographic database MEDLINE from 1986 onwards. 2. Hand searching the reference lists of trials and review articles identified

2005 Cochrane

77. Budesonide increased symptom free days in patients with recent onset mild asthma at an additional cost of US$0.42/day

Budesonide increased symptom free days in patients with recent onset mild asthma at an additional cost of US$0.42/day Budesonide increased symptom free days in patients with recent onset mild asthma at an additional cost of US$0.42/day | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Budesonide increased symptom free days in patients with recent onset mild asthma at an additional cost of US$0.42/day Article Text Economics Budesonide

Full Text available with Trip Pro

2005 Evidence-Based Medicine (Requires free registration)

78. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone Lofdahl C G, Ericsson A, Svensson K, Andreasson E Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the combination of budesonide and formoterol (B/F) in a single inhaler for the treatment of chronic obstructive pulmonary disease (COPD). The patients received two inhalations of B/F (160/4.5 microg) twice daily. Type of intervention Treatment. Economic study type

2005 NHS Economic Evaluation Database.

79. Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma

Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma Bruggenjurgen B, Selim D, Kardos P, Richter K, Vogelmeier C, Roll S, Meyer-Sabellek W, Buhl (...) R, Willich S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two strategies for the treatment of asthma were examined, adjustable maintenance versus fixed treatment. Both strategies were based on a combination of budesonide

2005 NHS Economic Evaluation Database.

80. Country-specific cost-effectiveness early intervention with budesonide in mild asthma

Country-specific cost-effectiveness early intervention with budesonide in mild asthma Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.